Top Page
RedHill Biopharma
(NASDAQ:RDHL)
RedHill Biopharma (RDHL) vs. SPDR S&P 500 ETF (SPY)
RedHill Biopharma Business Overview & Revenue Model
RedHill Biopharma Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.55M | 8.04M | 6.53M | 61.80M | 85.76M | 64.36M |
| Gross Profit | 6.16M | 4.85M | 3.07M | 28.46M | 36.35M | 27.47M |
| EBITDA | -7.91M | -7.59M | 26.27M | -22.18M | -63.03M | -54.98M |
| Net Income | -9.31M | -8.27M | 23.92M | -71.67M | -97.74M | -76.17M |
Balance Sheet | ||||||
| Total Assets | 18.38M | 18.04M | 23.05M | 158.87M | 181.19M | 180.24M |
| Cash, Cash Equivalents and Short-Term Investments | 2.87M | 4.62M | 6.36M | 19.98M | 38.00M | 29.79M |
| Total Debt | 214.00K | 356.00K | 1.17M | 122.69M | 87.81M | 86.90M |
| Total Liabilities | 22.79M | 22.73M | 20.98M | 207.27M | 172.31M | 166.38M |
| Stockholders Equity | -4.41M | -4.68M | 2.07M | -48.40M | 8.88M | 13.86M |
Cash Flow | ||||||
| Free Cash Flow | -8.21M | -9.38M | -35.83M | -29.38M | -65.16M | -102.35M |
| Operating Cash Flow | -8.20M | -9.37M | -35.82M | -29.18M | -65.05M | -48.58M |
| Investing Cash Flow | -12.00K | -9.00K | 3.99K | 8.30M | -8.14M | -35.65M |
| Financing Cash Flow | 3.78M | 8.42M | 21.38M | 11.45M | 73.46M | 84.37M |
RedHill Biopharma Technical Analysis
RedHill Biopharma Risk Analysis
RedHill Biopharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $5.58M | -1.50 | -76.14% | ― | 25.02% | 55.11% | |
51 Neutral | $2.49M | ― | 2.66% | ― | -27.81% | ― | |
47 Neutral | $6.21M | ― | ― | ― | ― | ― | |
44 Neutral | $2.69M | ― | ― | ― | ― | ― | |
42 Neutral | $5.67M | -1.10 | -42.47% | ― | -26.92% | 69.90% | |
32 Underperform | $3.24M | -0.09 | -9999.00% | ― | ― | 79.31% |
RedHill Biopharma Corporate Events
On January 27, 2026, RedHill Biopharma filed a Form 6‑K announcing an Extraordinary General Meeting of Shareholders to be held on March 5, 2026, in Tel Aviv. Shareholders and ADS holders of record as of January 23, 2026, will vote on four key proposals: granting restricted share units (RSUs) linked to ADSs to the company’s non‑executive directors, approving additional RSU awards to CEO and Chairman Dror Ben‑Asher and to Chief Commercial Officer and Director Rick D. Scruggs, and increasing the company’s authorized share capital. The board has recommended voting in favor of all proposals, signaling a push to enhance equity-based compensation for leadership while expanding the company’s capacity to issue new shares, a move that could support future financing flexibility but also has potential dilution implications for existing investors.
The most recent analyst rating on (RDHL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
On January 22, 2026, RedHill Biopharma filed a Form 6-K announcing an Extraordinary General Meeting of Shareholders to be held on March 5, 2026, in Tel Aviv. The meeting will ask shareholders to approve grants of restricted share units tied to ADSs for non-executive directors, CEO and chairman Dror Ben-Asher, and Chief Commercial Officer and director Rick D. Scruggs, as well as an increase in the company’s authorized share capital. Only holders of record of ADSs at the close of business on January 23, 2026, will be entitled to vote, with the board recommending support for all proposals, signaling an effort to align management and director incentives with shareholders while expanding the company’s capacity to issue additional equity in the future.
The most recent analyst rating on (RDHL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
On January 5, 2026, RedHill Biopharma announced further development progress for its proprietary once-daily extended-release ondansetron formulation RHB-102 (Bekinda) across multiple gastrointestinal indications, including a planned Phase 2 proof-of-concept study targeting gastrointestinal side effects associated with GLP-1/GIP receptor agonist therapies used for diabetes and weight loss. Supported by positive U.S. Phase 3 data in gastroenteritis/gastritis, Phase 2 data in IBS-D, a favorable pharmacokinetic study in oncology support, and decades of ondansetron use, RedHill is pursuing U.S. FDA approval of RHB-102 under the 505(b)(2) pathway for oncology support (with potential expansion to post-operative nausea and vomiting) and positioning the drug as a once-daily oral option that could reduce GI-driven discontinuation of GLP-1 treatments, potentially enhancing its partnership appeal and strengthening the company’s presence in the fast-growing GI and metabolic therapy support markets.
The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
On October 17, 2025, RedHill Biopharma completed a strategic transaction with Cumberland Pharmaceuticals involving Talicia®, its proprietary drug, by selling a 30% equity stake in newly formed Talicia Holdings Inc. (THI), which holds global rights to Talicia and manages its worldwide commercialization. Cumberland agreed to invest $4 million in two tranches in exchange for joint control of THI, leaving RedHill with a 70% stake but shared decision-making authority, leading RedHill to deconsolidate THI and treat its retained interest as an equity-method joint venture under IFRS; the company has now filed unaudited pro forma condensed consolidated financial information to illustrate how this loss of control, classification of Talicia operations as discontinued, and shift to joint venture accounting would have affected its historical results, signaling a structurally different financial profile for RedHill’s future reporting and Talicia-related earnings and risks.
The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
On December 19, 2025, RedHill Biopharma entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., giving the company, over a 36‑month period from that date, the discretionary right to sell up to $25 million of its ADSs to the investor, subject to trading‑volume, pricing and ownership caps, including a 9.99% beneficial ownership limit. As part of the initial funding step under this structure, RedHill on the same date issued 386,593 ADSs and a pre‑funded warrant for 590,446 ADSs for gross proceeds of $1 million, agreed to pay a 2% commitment fee partly in ADSs (including 122,130 ADSs already issued), and committed to registering all related ADS resales with the SEC, a move that provides a flexible but potentially dilutive equity financing mechanism to support the company’s capital needs.
The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
On December 15, 2025, RedHill Biopharma announced positive in vivo results for opaganib, showing its potential to reduce Chronic Lymphocytic Leukemia (CLL) cells by 50% when combined with venetoclax, a key CLL therapy. This development highlights opaganib’s potential as an add-on therapy to overcome venetoclax resistance, which is a significant therapeutic challenge in CLL treatment. The findings are part of ongoing research, including a Phase 2 study of opaganib with darolutamide in advanced prostate cancer, and may enhance RedHill’s position in the oncology market.
The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
RedHill Biopharma announced on December 1, 2025, that it successfully regained compliance with Nasdaq’s stockholders’ equity requirement as of November 26, 2025. This achievement supports RedHill’s strategic initiatives for 2025, including its partnership with Cumberland Pharmaceuticals and a focus on operational efficiency, potentially strengthening its market position and stakeholder confidence.
The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
On November 26, 2025, RedHill Biopharma Ltd. announced an increase in the maximum aggregate offering amount of its American Depositary Shares under an At The Market Offering Agreement with H.C. Wainwright & Co., LLC. This strategic move is expected to enhance the company’s financial flexibility and support its ongoing operations and growth initiatives in the competitive biopharmaceutical industry.
The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
RedHill Biopharma announced that the New York Supreme Court’s judgment in favor of the company against Kukbo Co. Ltd is now final and enforceable, with no further appeals possible. The court awarded RedHill over $10.5 million, including $8.6 million in the main judgment and $1.9 million for legal fees and expenses, with interest continuing to accrue. Additionally, RedHill secured a Korean court attachment to prevent Kukbo from disposing of assets before judgment enforcement, potentially strengthening RedHill’s financial position and market confidence.
The most recent analyst rating on (RDHL) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.